Replimune(REPL) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update · Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) scheduled for September and BLA submission planned for 2H 2024 · Enrollment of first patient in Phase 3 confirmatory trial of RP1 in advanced melanoma expected in Q3 2024 · Protocol finalized for registration-directed study of RP2 in uveal melanoma with study initiation activities underway Woburn, MA, Augus ...